Steady On For US FDA’s Novel Approvals At Mid-Year, But Another 2023 Is Unlikely

 
• By Bridget Silverman
half-way point
CDER’s PERFORMANCE HEADS BACK TO THE MEAN, WHILE CBER STAYS ABOVE AVERAGE. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers